Adenosine plays an important role in inflammation and tumor development, progression and responses to therapy. We show that an adenosine 2B receptor inhibitor (A2BRi) decreases both experimental and spontaneous metastasis and combines with chemotherapy or immune checkpoint inhibitors in mouse models of melanoma and triplenegative breast cancer (TNBC) metastasis. Decreased metastasis upon A2BR inhibition is independent of host A2BR and lymphocytes and myeloid cells. Knockdown of A2BR on mouse and human cancer cells reduces their metastasis in vivo and decreases their viability and colony forming ability, while transiently delaying cell cycle arrest in-vitro.
Introduction
Adenosine generated by ectoenzyme CD73 under hypoxic conditions has been described as an important regulator of immune responses in cancers and inflammatory disorders (1, 2) . Adenosine binds to four different G-protein-coupled adenosine receptor subtypes A1, A2A, A2B and A3 with different affinities allowing for diversity and cellular specificity in signaling pathway activity (3) . Antagonists of A2A and A2B adenosine receptors (A2AR and A2BR) have been shown to reduce tumor metastasis in mouse models of melanoma, ovarian, bladder and breast carcinoma (4, 5) . A2BR is a low affinity receptor but its expression is highly transcriptionally regulated by factors such as hypoxia inducible factor (HIF)-1α associated with inflammatory hypoxia (6) suggesting its role in tumor promotion.
In-vitro studies using cancer cell lines have shown an opposing role of A2BR on cancer cell proliferation and apoptosis, an effect that could depend on the concentration of adenosine receptor agonist, level of A2BR and the type of cancer cell lines. For example, NECA, 5 ' -(N-Ethylcarboxamido)adenosine, a non-specific adenosine receptor agonist was shown to activate caspase-3 and induce apoptosis in ovarian cancer cell lines with high A2BR expression (7) . Similarly, an adenosine analogue NECA was shown to enhance caspase-dependent apoptosis in response to chemotherapy in a human osteosarcoma cell line (8) and these effects were reversed by the A2BR antagonist PSB603 and siRNA knockdown to A2BR. Interestingly, a recent study also proposed tumor-promoting role of adenosine in an adenosine receptor-independent fashion (9) . In contrast, activation of A2BR was shown to induce proliferation of prostate cancer cells (10) and human glioblastoma cells (11) .
In-vivo studies have been less convincing regarding the mechanism of A2BR antagonists in controlling tumors (12) . A non-selective adenosine receptor antagonist (aminophylline) and a selective A2BR antagonist ATL801 was shown to reduce the growth of bladder and breast cancers when injected intratumorally (5) . Similarly, activation of A2BR enhanced the growth of primary melanoma. This effect was reversed by the A2BR antagonist PSB1115, and was associated with the reduced accumulation of myeloid derived suppressor cells (MDSCs) and increased NK cell and CD8 + T cell infiltration in the tumor tissue (13) . Antagonists for A2AR and A2BR were effective in reducing the metastasis of CD73 expressing tumors, but not CD73-negative tumors, suggesting CD73 as a putative biomarker for selecting patients for both these therapies (4) . Interestingly, unlike A2AR, A2BR blockade had no effect on NK cell function in mouse model of metastasis, suggesting a NK cell-independent mechanism contributing to increased metastasis of CD73 + tumors (4) . A2BR-induced VEGF production by MDSCs enhanced angiogenesis and promoted tumor growth in melanoma and Lewis lung carcinoma models (14, 15) . Further studies from Novitskiy et.al. suggested that dendritic cells (DC) activation via A2BR differentiated DC so that they expressed high levels of angiogenic and immunosuppressive factors such as VEGF, IL-10, TGF-beta, and IDO. When injected into the tumor bearing mice, these DCs increased the number of blood vessels and tumor weight (16) . Another study proposed A2BR receptor as a Fra-1 target gene contributing to metastatic activity of breast cancer cells (17) .
Thus far, research has supported the role of A2BR in promoting tumor growth, however 
Materials and Methods

Mice, Antibodies and Chemicals
C57BL
Lentiviral Knockdown of A2BR
Human and mouse A2BR was knocked down using ready to use GIPZ shRNA lentiviral particles from Dharmacon GE Life Sciences (Colorado, USA) as per manufacturer's instructions. Cells were then sorted for turbo-GFP expression and knockdown of A2BR expression was determined by RT-PCR and immunoblotting.
Colony formation assays and cell cycle analysis 500-1000 cells were seeded on 12 well plates and incubated for additional [7] [8] [9] [10] [11] [12] [13] [14] were determined using flow cytometry after staining with propidium iodide as described previously (22) .
Western blotting and real-time PCR
Western blotting was performed as described earlier ( 
Gene expression analyses
In order to evaluate the expression of A2BR as a prognostic indicator, gene expression was extracted and analysed from publicly available datasets as previously described (24) where the PAM50 molecular subtype classifier (24) was applied. Relapse free survival (RFS) was taken as the survival endpoint or each dataset, if unavailable, disease-free or distant metastases were used. Kaplan-Meier survival curves are constructed using tertiles of gene expression values and differences evaluated using Log-rank p values pooled across the tertiles. Cox regression analyses were also used to evaluate prognostic associations of the gene as a continuous variable. If more than one probe set was present per gene, the probe set with the highest variance was used. To achieve a comprehensive comparison between datasets, a robust linear scaling was applied to each gene (24) . All analyses have been performed using R version 3.2.3 (http://www.r-project.org/).
Statistical analysis
Statistical analysis was achieved using Graphpad Prism Software. Data was considered to be statistically significant where the p value was equal to or less than 0.05. Data were compared using a one-way ANOVA, Mann-Whitney U test or unpaired t test. Differences in survival were evaluated using a Log-rank (Mantel-Cox) test. Unless specified, all experiments were repeated at least twice with similar results. 
Results
High ADORA2B expression is associated with worse patient outcome CD73-adenosine signaling pathway has been implicated in promoting tumor growth and metastases (1, 2, (25) (26) (27) . We have previously shown that high CD73 expression is associated with a poor prognosis in the primary triple-negative breast cancer (TNBC) subtype and its overexpression in these tumors predicted chemoresistance to doxorubicin therapy (26) . Here we analyzed publicly available gene expression data for associations between A2BR expression and prognosis. High A2BR was significantly associated with poorer survival in breast cancer patients, and this effect seemed to be strongest in the TNBC patients ( Fig. 1 ), suggesting that A2BR is a tumor target of therapeutic interest for some breast cancers. Interestingly, high A2BR was not statistically associated with poor survival in the luminal or HER2+ subtypes ( Fig.1 ),
A2BRi suppresses experimental and spontaneous metastasis alone and in combination with other therapies
We analyzed the effect of A2BR inhibition in mouse models of experimental and spontaneous metastasis with cells expressing high levels of CD73. Consistent with our previous study (4), a selective antagonist of A2BR (A2BRi, PSB1115) significantly decreased experimental lung metastasis in the B16F10-CD73 hi melanoma ( Fig. 2A, B We next assessed the combinatorial effect of A2BRi with anti-PD-1 or anti-CTLA-4 monoclonal antibodies (mAb) in both melanoma and mammary cancer models of metastasis. We found that the combination of anti-PD-1 or anti-CTLA-4 with A2BRi was superior to either monotherapy alone in decreasing lung metastasis (Fig. 3A) and improving the survival of 4T1.2 tumor bearing mice (Fig. 3B) . Interestingly, the triple combination of A2BRi, anti-PD-1 and anti-CTLA-4 was more effective in the spontaneous model of 4T1.2 breast cancer metastasis, but not in the experimental metastasis of B16F10 melanoma, when compared with dual combination therapy ( Fig.   3A , B). Chemotherapy remains a standard of care treatment for TNBC patients.
Therefore, we investigated whether A2BRi improved the therapeutic effect of standard chemotherapeutic drug doxorubicin. A2BRi in combination with doxorubicin was more effective in improving the survival of 4T1.2 tumor bearing mice when compared to either monotherapy alone (Fig. 3C ). Collectively, this data suggests that A2BRi is an attractive anti-metastatic therapy and can improve survival when used in combination with standard chemotherapy and immune checkpoint inhibitor mAbs.
A2BRi suppression of metastasis is independent of T/NK cells and myeloid cells
A2B receptor is induced by hypoxia and has a broad cellular distribution in tumor microenvironment, including myeloid cells (28) . Therefore, we hypothesized that the anti-metastatic effect of A2BRi might be dependent on immune cells. Unlike anti-asGM1 antibody treated mice alone, depletion of NK cells by using anti-asGM1 antibody did not greatly increase the metastatic burden in lungs of mice treated with A2BRi
( Supplementary Fig. S1A ). Similarly, depletion of CD8 Fig. S2 ). Furthermore, A2BRi did not lose its therapeutic activity in groups of mice depleted of CD11c + dendritic cells (using CD11c-DOG transgenic mice, Supplementary Fig. S1C ) and macrophages (using clodronate liposomes, Supplementary   Fig. S1D ), suggesting that these immune cells are dispensable for A2BRi suppression of cancer metastasis.
A2BR on mouse cancer cells promote metastasis
We were encouraged to examine the function of A2BR on various mouse cancer cell lines. Suitable mAbs for detecting mouse and human A2BR by flow cytometry were not available. At the mRNA level, we found variable expression of A2BR on different cancer cell lines (Supplementary Fig. S3A ). Additionally, A2BR appeared to be more highly expressed on cancer cells than other adenosine receptors ( Supplementary Fig. S3 B, C) .
To assess the function of A2BR on cancer cells, we used lentiviral vectors to knockdown (KD) mouse A2BR expression from the mammary carcinomas EO771 and 4T1.2 ( Fig.   4A-C) , the LWT1 melanoma ( Supplementary Fig. S4C , E) and the RM1 prostate carcinoma ( Supplementary Fig. S4D, E) . Based on the A2BR expression at mRNA and protein levels in A2BR KD cells, we selected sh3 A2BR KD cells for EO771 cells and sh1 A2BR KD cells for other cell types in subsequent studies (Fig. 4 and Supplementary   Fig. S4 ).
Research. To evaluate the impact of A2BR loss on cancer cells, both shRNA (sh) control and A2BR KD cells were examined for their metastatic potential in-vivo. A2BR KD cells produced significantly fewer experimental metastases in mouse mammary carcinoma, melanoma and prostate carcinoma models (Fig. 4D, E, F) , consistent with what we observed after treatment with A2BR antagonist, PSB1115. Mice orthotopically inoculated with 4T1.2 A2BR KD mammary carcinoma survived longer than those inoculated with sh control 4T1.2 mammary carcinoma, post surgical resection (Fig. 4G) . The consistent effect of A2BR KD in reducing metastatic potential across various mouse cancer cell lines, and all three shRNA hairpins showing variable but significantly decreased metastatic burden compared to the sh control in the EO771 mammary carcinoma (Fig. 4D) , suggested that the observed phenotype was not an off-target effect of the lentiviral hairpins.
Interestingly, the knockdown of A2BR did not affect the growth of primary tumors in EO771 and 4T1.2 mammary carcinoma models ( Supplementary Fig. S4A, B) .
Host A2BR does not contribute significantly to metastasis
To further evaluate the role of host A2BR expression in controlling metastasis, we (Fig. 5B) . Furthermore, pro-metastatic activity of adenosine receptor agonist NECA was dependent partly on tumor A2BR as NECA increased the number of lung metastases of control sh E0771 tumor cells, but only partly increased the metastasis of sh3 A2BR KD E0771 tumor cells (P<0.007). The numbers of lung metastases were similar in WT and A2BR KO mice after NECA treatment suggesting that adenosine does not have its pro-metastatic effect through host A2BR (Fig.   5C ).
4T1.2 cells, but not sh1 A2BR KD cells
A2BR on human cancer cells promote metastasis
Given that high A2BR expression correlated with poor outcome in human breast cancer (Fig. 1) , we next studied the function of A2BR expression on human breast cancer cells.
We first performed A2BR mRNA expression analysis in breast cancer cell lines using the publically available database GOBO (29) . Using the GOBO dataset, we found that A2BR mRNA expression was associated with human TNBC cell lines (30) , with basal like subtype exhibiting the highest expression, while hormone receptor positive cell lines were negative for A2BR mRNA expression (Supplementary Fig. S5 ). Consistent with A2BR mRNA expression, CD73 was highly expressed in Basal B subtypes of breast cancer, including (data not shown). Next, we examined whether A2BRi reduced experimental metastasis in human TNBC tumor xenograft settings. A2BRi at a higher dose was slightly more effective in decreasing lung metastatic burden than at the lower dose (Fig. 6A, B) . A2BRi reduced experimental metastasis of both the parental and its metastatic variant MDA-MB-231-HM5 (CD73 hi A2BR hi ) cells (Fig 6A-C) . Moreover, we also found a similar result when CD73 + SUM159PT, an invasive metastatic cell line derived from anaplastic breast tumor was treated with A2BRi ( Supplementary Fig. S6A 
suggesting the effect of A2BRi-mediated metastatic inhibition is not cell line specific. To study the effect of A2BR expression on MDA-MB-231 cells in metastasis, A2BR KD cells were generated (Fig. 6D-E) and sh control and sh3 A2BR KD MDA-MB-231 cells were examined for their metastatic potential in-vivo. Knockdown of A2BR slowed down the growth of primary MDA-MB-231 tumors marginally but it did not reach statistical significance (Fig. 6F) . Notably, consistent with the data from the mouse cancer cell lines, A2BR KD MDA-MB-231 cells produced fewer experimental lung metastases compared to sh control cells (Fig. 6G) . Collectively, our data strongly suggest that inhibition of A2BR either using small molecule inhibitor or gene knockdown impaired lung metastases in human breast cancer cell lines.
A2BR regulates p-ERK activation, cell viability and cell cycle progression
Next we assessed the mechanism of the effect of A2BR expression on tumor metastasis. A2BR knockdown reduced the long-term colony formation ability (Fig. 7A-C) , which may be associated with the decreased viability in-vitro (Fig. 7D-F Table 1 ). Validation of the PCR array data, confirmed downregulation of FXYD5, a cell membrane glycoprotein known to reduce cell adhesion and drive metastasis (31) . This was observed in both mouse and human A2BR KD cancer cells compared to their sh control cells, suggesting the role of FXYD5 in promoting A2BR-dependent metastasis (32) (Supplementary Fig. S6D, E) . Moreover, consistent with reduced colony forming ability and delay in cell proliferation following A2BR depletion in multiple cancer lines, we found reduced phospho-ERK1/2 (Thr202/Tyr204) signaling (Fig. 7G ), but not phospho-STAT3 (Tyr705) or phospho-AKT (S473) (data not shown).
This was associated with reduced c-MYC and FOXM1 activity (Fig. 7G) ; both are downstream effectors of MAPK signaling. Reduced FOXM1 expression in A2BR KD cells encouraged us to examine cell cycle profile of sh control and A2BR KD cells.
Interestingly, both for mouse and human breast carcinoma cells, we observed A2BR knockdown was associated with transient delay in cell cycle progression with cell arresting in S/G2 delay (Fig. 8H, I ). Overall, these results suggest that A2BR may drive cancer metastasis by reducing cell adhesion and MAPK-dependent signaling activation. Furthermore, the A2BRi (PSB1115) was effective in reducing the metastasis of human TNBC xenografts in immunodeficient mice and was effective even in A2BR-deficient mice. Knockdown of A2BR on mouse and human cancer cell lines confirmed the critical role for tumor A2BR, rather than host A2BR, in metastasis and response to adenosine. Previously, CD73 overexpression was shown to be associated with poor clinical outcome for patients with ovarian (27) , prostate (25) and TNBC (26) . Using datasets from the same TNBC patients that had poor prognosis with increased CD73 expression, we observed that overexpression of A2BR was associated with poorer prognosis in TNBC.
The reduced viability and colony formation ability of A2BR KD cancer cells in-vitro
In fact, both CD73 and A2BR were highly expressed by Basal B type TNBC, suggesting that A2BR, like CD73, might be a therapeutic target in CD73 
